CATALAYER NEWS
FDA clears first Barth syndrome drug amid scrutiny of rare disease stance - BioPharma Dive
Source: BioPharma Dive · 2025-09-22
Full article text is available in the Catalayer news terminal.
MORE FROM BIOPHARMA DIVE
Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks - BioPharma Dive
2026-05-29
RELATED ON CATALAYER
Related Topics
Biotech & FDA NewsRELATED MARKETS
Prediction Markets